Company: NCEL
Filing Date: 2025-03-31
Form Type: 425
Source: 0001213900-25-025889
Chunk: 8

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: 425
Chunk 8
---
 Purchasers and their assigns pursuant to this Agreement, and (e) securities issued in
the Kadimastem Merger. No Variable Rate Transaction shall be deemed an Exempt Issuance.

“” means
the Foreign Corrupt Practices Act of 1977, as amended.

“” shall
mean the United States Food and Drug Administration.

"Full Consummation"
shall mean that the Capital Increase has been registered in the competent commercial register and the New Shares have been issued in accordance
with Section 2.8.

“”
shall mean any transaction in which (i) the Company or any of its Subsidiaries shall, directly or indirectly, in one or more related transactions,
(A) consolidate or merge with or into (whether or not the Company or any of its Subsidiaries is the surviving corporation) any other Person,
or (B) sell, lease, license, assign, transfer, convey or otherwise dispose of all or substantially all of its respective properties or
assets to any other Person, or (C) make, or allow any other Person to make, a purchase, tender or exchange offer that is accepted by the
holders of more than 50% of the outstanding shares of voting stock of the Company (not including any shares of voting stock of the Company
held by the Person or Persons making or party to, or associated or affiliated with the Persons making or party to, such purchase, tender
or exchange offer), or (D) consummate a stock or share exchange agreement or other business combination (including, without limitation,
a reorganization, recapitalization, spin-off or scheme of arrangement) with any other Person whereby such other Person acquires more than
50% of the outstanding shares of voting stock of the Company (not including any shares of voting stock of the Company held by the other
Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share
exchange agreement or other business combination), or (E) reorganize, recapitalize or reclassify the Common Stock, or (ii) any “person”
or “group” (as these terms are used for purposes of Sections 13(d) and 14(d) of the 1934 Act and the rules and regulations
promulgated thereunder) is or shall become the “beneficial owner” (as defined in Rule 13d-3 under the 1934 Act), directly
or indirectly, of 50% of the